Adjunctive Use of Atypical Antipsychotics for Treatment‐Resistant Generalized Anxiety Disorder
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Generalized anxiety disorder (GAD) is a common, chronic mental illness that has a significant burden on the patient's quality of life. Treatment for GAD routinely consists of monotherapy with a proven anxiolytic such as an antidepressant or benzodiazepine, but many patients do not respond fully to these drugs, and additional treatment may be needed. Therefore, we reviewed the safety and efficacy of atypical antipsychotics as adjunct therapy to standard GAD pharmacotherapy in patients deemed treatment resistant. We performed a literature search of the MEDLINE database for English‐language articles published from January 1966‐May 2009. Identified articles were evaluated, and only open‐label trials and randomized controlled trials (RCTs) were included in the review. Relevant references from the articles were also evaluated. Only a few reports of large‐scale RCTs that assessed an atypical antipsychotic for treatment‐resistant GAD have been published. Articles were found for five of the eight currently available atypical antipsychotics, but not for asenapine, clozapine, and paliperidone. Several open‐label trials and smaller RCTs support the need for further evaluation of aripiprazole and quetiapine for treatment‐refractory GAD, although one quetiapine trial demonstrated negative results. There is disparate data for risperidone, with one open‐label trial and one small RCT showing positive results and one large RCT showing negative results. One open‐label trial of ziprasidone and one RCT of olanzapine both showed beneficial effects of the drugs. Adverse effects were specific to each agent, with weight gain being the most common, but many studies did not monitor systematically for lipid level, weight, or glucose level changes. Although data suggest efficacy regarding the use of atypical antipsychotics for augmentation of treatment‐refractory GAD, more rigorous studies (large, double‐blind, placebo‐controlled trials) on the safety and efficacy of these agents are needed in order to recommend their use in patients with GAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey
Wittchen, H.-U. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950050015002 · Cited by 967 · cited 1×
“In fact, 90% of patients with GAD have at least one other psychiatric disorder, with the most common comorbid disorder being depression, at a frequency of approximately 62%.(4) Other common comorbidities with GAD include dysthymia (42%), substance abuse (37%), other anxiety disorders (35%), and bipolar disorder (17%).”
BackgroundTohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Generalized anxiety disorder: prevalence, burden, and cost to society
Wittchen, H.-U. (2002) · Depression and Anxiety · doi:10.1002/da.10065 · Cited by 733
A single dose of citalopram increases fear recognition in healthy subjects
Browning, M., Reid, C., Cowen, P. J., Goodwin, G. M., & Harmer, C. J. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106074062 · Cited by 245 · cited 1×
“Although not FDA approved, citalopram has also been found to be effective for the treatment of GAD.(16) Whereas benzodiazepines have been shown effective for shortterm anxiety, they may worsen depression, a common comorbidity of GAD, and cause other cognitive adverse effects such as sedation and anterograde amnesia.”
BackgroundPhenomenology and Course of Generalised Anxiety Disorder
Yonkers, K. A., Warshaw, M. G., Massion, A. O., & Keller, M. B. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.168.3.308 · Cited by 242
Judd, L. L., Kessler, R. C., PauIus, M. P., Zeller, P. V., Wittchen, H. ‐., & Kunovac, J. L. (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb05960.x · Cited by 222
McIntyre, A., Gendron, A., & McIntyre, A. (2007) · Depression and Anxiety · doi:10.1002/da.20275 · Cited by 145
Hirschfeld, R. M. A., Weisler, R. H., Raines, S. R., Macfadden, W., & BOLDER Study Group (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0304 · Cited by 116
Lack of Relationship Between Long-Term Use of Benzodiazepines and Escalation to High Dosages
Soumerai, S. B., Simoni-Wastila, L., Singer, C., Mah, C., Gao, X., Salzman, C., & Ross-Degnan, D. (2003) · Psychiatric Services · doi:10.1176/appi.ps.54.7.1006 · Cited by 104 · cited 1×
“Individuals with a history of substance abuse or dependence should not use benzodiazepines, but patients with no such history rarely abuse these agents and can use them safely.(17) Buspirone and pregabalin also have proven efficacy for GAD.”
Aripiprazole as Augmentation Treatment of Refractory Generalized Anxiety Disorder and Panic Disorder
Hoge, E. A., Worthington, J. J., Kaufman, R. E., Delong, H. R., Pollack, M. H., & Simon, N. M. (2008) · CNS Spectrums · doi:10.1017/s109285290001676x · Cited by 58 · cited 1×
“A fourth open-label trial was identified.(33) Patients who had refractory GAD or panic disorder and were receiving pharmacotherapy at therapeutic doses had aripiprazole added to their treatment for 8 weeks.”
Background
Cited by
Olfson, M., Blanco, C., Liu, S.-M., Wang, S., & Correll, C. U. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.647 · Cited by 352
Andrews, G., Bell, C., Boyce, P., Gale, C., Lampe, L., Marwat, O., Rapee, R., & Wilkins, G. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418799453 · Cited by 243
Teed, A. R., Feinstein, J. S., Puhl, M., Lapidus, R. C., Upshaw, V., Kuplicki, R. T., Bodurka, J., Ajijola, O. A., Kaye, W. H., Thompson, W. K., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.4225 · Cited by 79
Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review
Bokma, W. A., Wetzer, G. A. A. M., Gehrels, J. B., Penninx, B. W. J. H., Batelaan, N. M., & Balkom, A. L. J. M. (2019) · Depression and Anxiety · doi:10.1002/da.22895 · Cited by 58
Schoenfeld, T. J., Kloth, A. D., Hsueh, B., Runkle, M. B., Kane, G. A., Wang, S. S.-H., & Gould, E. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3234-13.2014 · Cited by 49
“Anxiety disorders are among the most prevalent of psychiatric illnesses (Kessler et al., 2005) and many of the available pharmacological treatments for anxiety do not produce sufficient relief of symptoms or do so with unwanted side effects (Cloos and Ferreira, 2009; Lorenz et al., 2010).”
Background
Metadata
- Authors
- Lorenz, R. A., Jackson, C. W., & Saitz, M.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2010-09
- Volume
- 30
- Issue
- 9
- Pages
- 942-951
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2164941713
- Cited by
- 32
- References
- 11
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.